NIKKEI 225
38,356.06 +176.60 (+0.46%) HANG SENG
19,073.71 -41.35 (-0.22%) CRUDE OIL
78.44 +0.42 (+0.54%) GOLD FUTURES
2,362.40 +2.50 (+0.11%) DOW
39,558.11 +126.60 (+0.32%) Bitcoin GBP
48,947.99 -987.54 (-1.98%)
Azitra, Inc. (AZTR)
After hours:
| Previous close | 0.1880 |
| Open | 0.1850 |
| Bid | 0.1731 x 900 |
| Ask | 0.1753 x 1400 |
| Day's range | 0.1710 - 0.1881 |
| 52-week range | 0.1610 - 5.1800 |
| Volume | |
| Avg. volume | 817,140 |
| Market cap | 5.067M |
| Beta (5Y monthly) | N/A |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -1.8300 |
| Earnings date | N/A |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | 3.50 |
- Business Wire
Azitra, Inc. Announces Positive Preclinical Data of ATR-12 and Clinical Design in Netherton Syndrome Presented at the ASGCT Annual Meeting
BRANFORD, Conn., May 10, 2024--Azitra, Inc. (NYSE American: AZTR), a clinical-stage biopharmaceutical company focused on developing innovative therapies for precision dermatology, today announced preclinical data from the Company’s platform and pipeline. The data are being presented on Friday, May 10, 2024, in two oral sessions entitled "Engineered Staphylococcus Epidermidis as a Protein Delivery System for Treating Skin Diseases" and "Staphylococcus epidermidis Strain Expressing LEKTI-D6 (ATR12
- Business Wire
Azitra, Inc. Announces Q1 2024 Financial Results and Provides Business Updates
BRANFORD, Conn., May 09, 2024--Azitra, Inc. (NYSE American: AZTR), a clinical-stage biopharmaceutical company focused on developing innovative therapies for precision dermatology, today reported financial results for the three months ended March 31, 2024, and provided a business update.
- Business Wire
Azitra, Inc. Announces New Preclinical Data to be Presented at the American Society of Gene and Cell Therapy Meeting
BRANFORD, Conn., April 22, 2024--Azitra, Inc. (NYSE American: AZTR), a clinical-stage biopharmaceutical company focused on developing innovative therapies for precision dermatology, today announced preclinical data from the Company’s platform and pipeline. The data will be presented on Friday, May 10, 2024, in two oral sessions entitled "Engineered Staphylococcus Epidermidis as a Protein Delivery System for Treating Skin Diseases" and "Staphylococcus epidermidis Strain Expressing LEKTI-D6 (ATR12
